Stock IGN INNO-GENE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Inno-Gene S.A.

Equities

IGN

PLINNGN00015

Biotechnology & Medical Research

End-of-day quote Warsaw S.E.
Other stock markets
 18:00:00 2024-05-13 EDT 		5-day change 1st Jan Change
1.76 PLN +0.28% Intraday chart for Inno-Gene S.A. -1.68% -20.00%
02-14 Inno-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
02-14 Inno-Gene S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 19.61 13.68 11.74 113.5 54.73 35.12
Enterprise Value (EV) 1 19.62 14.42 12.67 115.8 49.33 39.09
P/E ratio 24.4 x 32.4 x -71.2 x 72.1 x 8.91 x -17.6 x
Yield - - - - - -
Capitalization / Revenue 6.54 x 4.86 x 8.66 x 24.2 x 1.83 x 117 x
EV / Revenue 6.54 x 5.12 x 9.34 x 24.8 x 1.65 x 130 x
EV / EBITDA 13.4 x 23.6 x -68.5 x 47.9 x 4.64 x -77.4 x
EV / FCF 18.5 x -6.39 x -134 x -153 x 7.4 x -53.7 x
FCF Yield 5.4% -15.6% -0.75% -0.65% 13.5% -1.86%
Price to Book 10.8 x 5.86 x 5.16 x 29.6 x 6.71 x -61.3 x
Nbr of stocks (in thousands) 5,701 5,701 5,701 5,701 5,701 5,701
Reference price 2 3.440 2.400 2.060 19.90 9.600 6.160
Announcement Date 18-05-29 19-05-31 20-07-30 21-05-31 22-05-31 23-08-31
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 2.999 2.818 1.357 4.679 29.88 0.3
EBITDA 1 1.467 0.6116 -0.1849 2.42 10.63 -0.505
EBIT 1 0.6897 0.4314 -0.3111 1.476 9.595 -1.073
Operating Margin 23% 15.31% -22.93% 31.55% 32.11% -357.67%
Earnings before Tax (EBT) 1 0.5803 0.3239 -0.2715 1.662 8.524 -1.947
Net income 1 0.8041 0.4226 -0.1648 1.573 6.143 -1.98
Net margin 26.81% 15% -12.15% 33.61% 20.56% -660%
EPS 2 0.1410 0.0741 -0.0289 0.2759 1.077 -0.3500
Free Cash Flow 1 1.059 -2.255 -0.0944 -0.7565 6.668 -0.7278
FCF margin 35.33% -80.03% -6.96% -16.17% 22.31% -242.6%
FCF Conversion (EBITDA) 72.23% - - - 62.73% -
FCF Conversion (Net income) 131.74% - - - 108.56% -
Dividend per Share - - - - - -
Announcement Date 18-05-29 19-05-31 20-07-30 21-05-31 22-05-31 23-08-31
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 0 0.74 0.92 2.37 - 3.98
Net Cash position 1 - - - - 5.4 -
Leverage (Debt/EBITDA) 0.003402 x 1.204 x -4.997 x 0.9778 x - -7.873 x
Free Cash Flow 1 1.06 -2.26 -0.09 -0.76 6.67 -0.73
ROE (net income / shareholders' equity) 23.6% 12.2% -11.1% 45.7% 115% -52.2%
ROA (Net income/ Total Assets) 2.21% 1.43% -1.1% 4.93% 44.8% -7.12%
Assets 1 36.39 29.64 15.05 31.9 13.72 27.79
Book Value Per Share 2 0.3200 0.4100 0.4000 0.6700 1.430 -0.1000
Cash Flow per Share 2 0.1400 0.0100 0 0.0500 0.6900 -
Capex - 3.08 0.96 0.02 0.08 -
Capex / Sales - 109.14% 70.82% 0.52% 0.27% -
Announcement Date 18-05-29 19-05-31 20-07-30 21-05-31 22-05-31 23-08-31
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
INNO-GENE S.A. Stock Inno-Gene S.A.
-20.00% 2.76M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-27.21% 9.96B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-8.13% 3.03B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+35.30% 3B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.73% 2.18B
VERACYTE, INC. Stock Veracyte, Inc.
-14.25% 1.76B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+66.11% 1.42B
CAREDX, INC Stock CareDx, Inc
+26.50% 794M
SEEGENE, INC. Stock Seegene, Inc.
-2.18% 756M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+3.18% 305M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. IGN Stock
  4. Financials Inno-Gene S.A.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW